Details for Patent: 8,609,862

Which drugs does patent 8,609,862 protect, and when does it expire?

Patent 8,609,862 protects ISTURISA and is included in one NDA.

This patent has forty-six patent family members in thirty-one countries.

Summary for Patent: 8,609,862

Title:	Use of an adrenal hormone-modifying agent
Abstract:	The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): ##STR00001## wherein n is 1 or 3; R is hydrogen or --C(O)N(R.sub.a)(R.sub.b) wherein R.sub.a and R.sub.b are independently --(C.sub.1-C.sub.4)alkyl, or --(C.sub.1-C.sub.4)alkyl-(C.sub.5-C.sub.7)aryl, wherein each of R.sub.a and R.sub.b is optionally substituted by --(C.sub.1-C.sub.4)alkoxy; R.sub.1, R.sub.2, and R.sub.3, are independently hydrogen, halogen, cyano or --(C.sub.6-C.sub.10) aryl, wherein said --(C.sub.6-C.sub.10)aryl is optionally substituted by halogen, with the proviso that no more than one of R.sub.1, R.sub.2, and R.sub.3 is hydrogen; and R.sub.4 and R.sub.5 are hydrogen; or a pharmaceutically acceptable salt thereof.
Inventor(s):	Hu; Qi-Ying (Needham, MA), Ksander; Gary Michael (Amherst, NH), Meredith; Erik (Hudson, MA), Monovich; Lauren G. (Belmont, MA), Papillon; Julien (Somerville, MA), Schumacher; Christoph (Bettingen, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/521,548
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,609,862

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-001	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-002	Mar 6, 2020		RX	Yes	No						CUSHING'S DISEASE
Recordati Rare	ISTURISA	osilodrostat phosphate	TABLET;ORAL	212801-003	Mar 6, 2020		DISCN	Yes	No						CUSHING'S DISEASE

Foreign Priority and PCT Information for Patent: 8,609,862

PCT Information
PCT Filed	January 13, 2011	PCT Application Number:	PCT/US2011/021100
PCT Publication Date:	July 21, 2011	PCT Publication Number:	WO2011/088188

International Family Members for US Patent 8,609,862

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011205290
Brazil	112012017458
Canada	2786443